STRATA Skin Sciences (SSKN) Competitors

Microbot Medical (NASDAQ:MBOT) and STRATA Skin Sciences (NASDAQ:SSKN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, dividends, profitability, earnings, media sentiment, valuation and risk.

Do institutionals and insiders hold more shares of MBOT or SSKN?

16.3% of Microbot Medical shares are owned by institutional investors. Comparatively, 32.4% of STRATA Skin Sciences shares are owned by institutional investors. 10.6% of Microbot Medical shares are owned by insiders. Comparatively, 40.4% of STRATA Skin Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Which has more volatility & risk, MBOT or SSKN?

Microbot Medical has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500. Comparatively, STRATA Skin Sciences has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500.

Does the media refer more to MBOT or SSKN?

In the previous week, Microbot Medical had 6 more articles in the media than STRATA Skin Sciences. MarketBeat recorded 8 mentions for Microbot Medical and 2 mentions for STRATA Skin Sciences. Microbot Medical's average media sentiment score of 0.61 beat STRATA Skin Sciences' score of 0.20 indicating that STRATA Skin Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Microbot Medical	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
STRATA Skin Sciences	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor MBOT or SSKN?

Microbot Medical received 123 more outperform votes than STRATA Skin Sciences when rated by MarketBeat users. Likewise, 70.61% of users gave Microbot Medical an outperform vote while only 63.90% of users gave STRATA Skin Sciences an outperform vote.

Company	Underperform	Outperform
Microbot Medical	Outperform Votes 346 70.61%	Underperform Votes 144 29.39%
STRATA Skin Sciences	Outperform Votes 223 63.90%	Underperform Votes 126 36.10%

Do analysts recommend MBOT or SSKN?

Microbot Medical presently has a consensus target price of $7.00, indicating a potential upside of 709.25%. STRATA Skin Sciences has a consensus target price of $3.80, indicating a potential upside of 597.25%. Given STRATA Skin Sciences' higher probable upside, research analysts clearly believe Microbot Medical is more favorable than STRATA Skin Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Microbot Medical	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
STRATA Skin Sciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Which has stronger valuation & earnings, MBOT or SSKN?

Microbot Medical has higher earnings, but lower revenue than STRATA Skin Sciences. STRATA Skin Sciences is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Microbot Medical	N/A	N/A	-$10.74M	-$1.08	-0.80
STRATA Skin Sciences	$33.36M	0.57	-$10.83M	-$0.31	-1.76

Is MBOT or SSKN more profitable?

Microbot Medical has a net margin of 0.00% compared to Microbot Medical's net margin of -32.47%. Microbot Medical's return on equity of -52.50% beat STRATA Skin Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Microbot Medical	N/A	-164.13%	-125.22%
STRATA Skin Sciences	-32.47%	-52.50%	-17.66%

Summary

Microbot Medical beats STRATA Skin Sciences on 9 of the 16 factors compared between the two stocks.